Glycopyrrolate Improves Disability From Sialorrhea in Parkinson's Disease: A 12‐Week Controlled Trial
- 13 July 2020
- journal article
- research article
- Published by Wiley in Movement Disorders
- Vol. 35 (12) , 2319-2323
Abstract
Objective: The objective of this study was to assess the 12‐week efficacy and safety of oral glycopyrrolate for moderate‐to‐severe sialorrhea in Parkinson's disease (PD).Background: Chronic moderate‐to‐severe sialorrhea has a negative impact on quality of life in PD. There is no robust evidence for oral treatments for sialorrhea longer than 1 week.Methods: This was a 12‐week, double‐blinded, placebo‐controlled, parallel phase II study in patients with PD and Movement Disorder Society–Unified Parkinson's Disease Rating Scale item 2.2 > 2. The intervention was glycopyrrolate up to 4.5 mg/d; the primary outcome was sialorrhea related–disability (Radboud Oral Motor Inventory for Parkinson's Disease–Saliva). We used an intention‐to‐treat analysis. A P < 0.05 was deemed significant.Results: We recruited 28 patients (age, 71.1 ± 6.9 years; PD duration, 11.4 ± 7.2 years; Radboud Oral Motor Inventory for Parkinson's Disease–Saliva, 22.4 ± 5.7). Glycopyrrolate was superior to placebo at 12 weeks in the Radboud Oral Motor Inventory for Parkinson's Disease–Saliva (between‐group difference, 5.3; 95% confidence interval, 1.0–9.6). Dry mouth was the most common adverse event (glycopyrrolate, n = 6; placebo, n = 2).Conclusions: The results support the efficacy of glycopyrrolate to treat sialorrhea‐related disability up to 12 weeks and contribute to addressing unmet nonmotor care needs in PD. © 2020 International Parkinson and Movement Disorder SocietyKeywords
Funding Information
- Movement Disorders Research Fund, Toronto General and Western Hospital Foundation
- Parkinson Research Consortium
This publication has 10 references indexed in Scilit:
- Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in AdultsJAMA Neurology, 2020
- Long-term incobotulinumtoxinA treatment for chronic sialorrhea: Efficacy and safety over 64 weeksParkinsonism & Related Disorders, 2020
- Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine reviewMovement Disorders, 2019
- Reproducibility and Validity of Patient-Rated Assessment of Speech, Swallowing, and Saliva Control in Parkinson's DiseaseArchives of Physical Medicine and Rehabilitation, 2011
- Diurnal and nocturnal drooling in Parkinson’s diseaseJournal of Neurology, 2011
- Glycopyrrolate for sialorrhea in Parkinson diseaseNeurology, 2010
- Prevalence and definition of drooling in Parkinson’s disease: a systematic reviewJournal of Neurology, 2009
- Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing resultsMovement Disorders, 2008
- Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidanceHealth and Quality of Life Outcomes, 2006
- Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.Journal of Neurology, Neurosurgery & Psychiatry, 1992